Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · Real-Time Price · USD
2.680
-0.190 (-6.62%)
At close: Feb 21, 2025, 4:00 PM
2.660
-0.020 (-0.75%)
After-hours: Feb 21, 2025, 5:05 PM EST
Alpha Tau Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Alpha Tau Medical stock have an average target of 8.00, with a low estimate of 7.00 and a high estimate of 9.00. The average target predicts an increase of 198.51% from the current stock price of 2.68.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 22, 2024.
Analyst Ratings
The average analyst rating for Alpha Tau Medical stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
Buy | 2 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +235.82% | Nov 22, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +235.82% | Oct 23, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +235.82% | Oct 11, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +235.82% | Aug 20, 2024 |
Piper Sandler | Piper Sandler | Buy Reiterates $7 | Buy | Reiterates | $7 | +161.19% | Aug 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.45
from -0.42
EPS Next Year
-0.48
from -0.45
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | n/a | 41.1M | |||
Avg | n/a | n/a | 39.9M | |||
Low | n/a | n/a | 38.4M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -0.46 | -0.41 | 0.14 | |||
Avg | -0.45 | -0.48 | -0.20 | |||
Low | -0.44 | -0.50 | -0.51 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.